Yuhan signs license agreement for new hepatitis B treatment

Published: 2011-04-01 06:59:00

Updated: 2011-04-01 06:59:00

Yuhan Corp. said Wednesday that the company has concluded an agreement with the U.S.-based Gilead Sciences Inc., under which Yuhan will have an exclusive right to market Viread (tenofovir disoproxil fumarate) for treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B virus (HBV), in Korea.

The Korea Food and Drug Administration granted marketing approval for Vire...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.